Public Employees Retirement System of Ohio Has $600,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Public Employees Retirement System of Ohio lifted its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 81.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 106,356 shares of the company's stock after purchasing an additional 47,656 shares during the period. Public Employees Retirement System of Ohio owned about 0.13% of Verve Therapeutics worth $600,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of VERV. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Verve Therapeutics by 4.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,818 shares of the company's stock worth $676,000 after acquiring an additional 4,777 shares during the last quarter. Vestal Point Capital LP lifted its holdings in Verve Therapeutics by 22.9% in the fourth quarter. Vestal Point Capital LP now owns 645,000 shares of the company's stock worth $3,638,000 after acquiring an additional 120,000 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in Verve Therapeutics by 58.8% in the fourth quarter. Two Sigma Advisers LP now owns 293,200 shares of the company's stock worth $1,654,000 after acquiring an additional 108,600 shares during the last quarter. Two Sigma Investments LP lifted its holdings in Verve Therapeutics by 32.5% in the fourth quarter. Two Sigma Investments LP now owns 570,304 shares of the company's stock worth $3,217,000 after acquiring an additional 140,030 shares during the last quarter. Finally, Tema Etfs LLC bought a new position in Verve Therapeutics in the fourth quarter worth about $503,000. Institutional investors own 97.11% of the company's stock.

Verve Therapeutics Stock Up 8.3%

Verve Therapeutics stock traded up $0.44 during mid-day trading on Thursday, hitting $5.73. The company's stock had a trading volume of 6,956,516 shares, compared to its average volume of 1,935,784. The stock has a market capitalization of $510.79 million, a P/E ratio of -2.33 and a beta of 1.67. Verve Therapeutics, Inc. has a twelve month low of $2.86 and a twelve month high of $9.31. The stock's fifty day moving average price is $4.46 and its two-hundred day moving average price is $5.73.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.36. The firm had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Equities analysts expect that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. William Blair restated an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. HC Wainwright raised their price target on shares of Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, April 14th. Guggenheim raised their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Finally, Wall Street Zen upgraded shares of Verve Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.